Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.

ABSTRACT: Dasatinib treatment markedly increases the number of large granular lymphocytes including natural killer (NK) cells in a proportion of Ph⁺ leukemia patients, which associates with a better prognosis. In-depth immune profiling of NK cells can predict therapeutic response in these patients. In the present study, we showed that CD56-negative (CD56^neg ) NK cells increased exclusively in cytomegalovirus-seropositive (CMV⁺ ) patients treated with dasatinib. The increase longitudinally paralleled with progressive differentiation of CD56^dim NK cells during dasatinib therapy driven by CMV reactivation as shown by principal component analysis on 19 NK cell markers. The CD56^neg NK cells showed downregulation of NK-activating receptors, upregulati

SUBMITTER: Ishiyama KI 

PROVIDER: S-EPMC7893985 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature